FDA consumer context worth knowing: The FDA has published consumer guidance expressing concerns about unapproved GLP-1 products marketed for weight loss, including quality and dosing concerns and, in some cases, products that may use semaglutide salt forms that are not the same active ingredient as the FDA-approved reference drug
SNAC temporarily opens tight junctions in the stomach lining, allowing the peptide to pass through
Michigan and Virginia tightened eligibility to morbid obesity thresholds
Injected semaglutide is well-studied and known for its strong effectiveness
Since fibrosis is the most compelling predictor of outcomes, current and future therapies must focus on improving fibrosis by indirectly reducing pro-fibrotic inflammatory signaling or directly abrogating fibrosis
Three 30mg vials covers 90mg, sufficient for weeks 9-16 with some remaining